Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity.
Ackerman SE, Pearson CI, Gregorio JD, Gonzalez JC, Kenkel JA, Hartmann FJ, Luo A, Ho PY, LeBlanc H, Blum LK, Kimmey SC, Luo A, Nguyen ML, Paik JC, Sheu LY, Ackerman B, Lee A, Li H, Melrose J, Laura RP, Ramani VC, Henning KA, Jackson DY, Safina BS, Yonehiro G, Devens BH, Carmi Y, Chapin SJ, Bendall SC, Kowanetz M, Dornan D, Engleman EG, Alonso MN. Ackerman SE, et al. Among authors: ho py. Nat Cancer. 2021 Jan;2(1):18-33. doi: 10.1038/s43018-020-00136-x. Epub 2020 Dec 7. Nat Cancer. 2021. PMID: 35121890 Free PMC article.
Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy.
Barkal AA, Weiskopf K, Kao KS, Gordon SR, Rosental B, Yiu YY, George BM, Markovic M, Ring NG, Tsai JM, McKenna KM, Ho PY, Cheng RZ, Chen JY, Barkal LJ, Ring AM, Weissman IL, Maute RL. Barkal AA, et al. Among authors: ho py. Nat Immunol. 2018 Jan;19(1):76-84. doi: 10.1038/s41590-017-0004-z. Epub 2017 Nov 27. Nat Immunol. 2018. PMID: 29180808 Free PMC article.
Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.
Upton R, Banuelos A, Feng D, Biswas T, Kao K, McKenna K, Willingham S, Ho PY, Rosental B, Tal MC, Raveh T, Volkmer JP, Pegram MD, Weissman IL. Upton R, et al. Among authors: ho py. Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):e2026849118. doi: 10.1073/pnas.2026849118. Proc Natl Acad Sci U S A. 2021. PMID: 34257155 Free PMC article.
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.
Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, George S, Hughes BGM, Hellmann MD, Shepard DR, Rini BI, Kummar S, Weise AM, Riese MJ, Markman B, Emens LA, Mahadevan D, Luke JJ, Laport G, Brody JD, Hernandez-Aya L, Bonomi P, Goldman JW, Berim L, Renouf DJ, Goodwin RA, Munneke B, Ho PY, Hsieh J, McCaffery I, Kwei L, Willingham SB, Miller RA. Fong L, et al. Among authors: ho py. Cancer Discov. 2020 Jan;10(1):40-53. doi: 10.1158/2159-8290.CD-19-0980. Epub 2019 Nov 15. Cancer Discov. 2020. PMID: 31732494 Free PMC article. Clinical Trial.
Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk.
Feng M, Chen JY, Weissman-Tsukamoto R, Volkmer JP, Ho PY, McKenna KM, Cheshier S, Zhang M, Guo N, Gip P, Mitra SS, Weissman IL. Feng M, et al. Among authors: ho py. Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):2145-50. doi: 10.1073/pnas.1424907112. Epub 2015 Feb 2. Proc Natl Acad Sci U S A. 2015. PMID: 25646432 Free PMC article.
165 results